Cargando…

Efficacy of chemotherapy after hormone therapy for hormone receptor–positive metastatic breast cancer

OBJECTIVE: According to the guidelines for metastatic breast cancer, hormone therapy for hormone receptor–positive metastatic breast cancer without life-threatening metastasis should be received prior to chemotherapy. Previous trials have investigated the sensitivity of chemotherapy for preoperative...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mori, Ryutaro, Nagao, Yasuko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2014
Materias:	Original Manuscript
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4607235/ https://www.ncbi.nlm.nih.gov/pubmed/26770749 http://dx.doi.org/10.1177/2050312114557376

Ejemplares similares

Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer
por: Miyahara, Kana, et al.
Publicado: (2022)

High-Dose Toremifene for Fulvestrant-Resistant Metastatic Breast Cancer: A Report of Two Cases
por: Mori, Ryutaro, et al.
Publicado: (2014)

Health-related Quality of Life in Hormone Receptor-Positive Early Breast Cancer: Analyses From the Surveillance, Epidemiology, and End Results Medicare Health Outcomes Survey
por: Nabulsi, Nadia A, et al.
Publicado: (2022)

Two Cases of Mastectomy after Paclitaxel + Bevacizumab Therapy for Locally Advanced Breast Cancer
por: Shinoda, Chika, et al.
Publicado: (2014)

Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
por: Bian, Li, et al.
Publicado: (2020)

Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
por: Yuan, Yang, et al.
Publicado: (2023)

Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
por: D’Souza, Anishka, et al.
Publicado: (2018)

Oncologic efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy
por: Choi, Hee Jun, et al.
Publicado: (2023)

Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib
por: Dhakal, Ajay, et al.
Publicado: (2020)

RETRACTION: Challenges of Combined Everolimus/Endocrine Therapy in Hormone Receptor-Positive Metastatic Breast Cancer
por: Porta, Camillo
Publicado: (2014)

Combination of Osimertinib with Concurrent Chemotherapy and Hormonal Therapy for Synchronous NSCLC, Hormone Receptor-Positive Breast Cancer, and Triple-Negative Breast Cancer: Case Report
por: Park, Changsu L., et al.
Publicado: (2023)

Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2019)

Treatment Considerations for the Management of Patients With Hormone Receptor–Positive Metastatic Breast Cancer
por: Visovsky, Constance
Publicado: (2014)

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Ballinger, Tarah J., et al.
Publicado: (2018)

Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies
por: Mouabbi, Jason A., et al.
Publicado: (2022)

Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy
por: Yang, Libo, et al.
Publicado: (2018)

Combination Therapies in Advanced, Hormone Receptor–Positive Breast Cancer
por: Olson, Emily
Publicado: (2018)

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
por: Fabi, Alessandra, et al.
Publicado: (2012)

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
por: Turner, Nicholas C., et al.
Publicado: (2019)

Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea
por: Beom, Seung Hoon, et al.
Publicado: (2017)

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
por: Hua, Xin, et al.
Publicado: (2022)

Weight Gain after Hormone Receptor-Positive Breast Cancer
por: Goyal, Archita, et al.
Publicado: (2022)

An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor– positive early breast cancer
por: Verma, S., et al.
Publicado: (2009)

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
por: Keenan, Tanya E., et al.
Publicado: (2021)

Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer
por: Lin, Mingxi, et al.
Publicado: (2021)

Recent Developments in the Therapeutic Landscape of Advanced or Metastatic Hormone Receptor–Positive Breast Cancer
por: Lee, Eunice Yoojin, et al.
Publicado: (2023)

3365 Treatment Interruptions and Early Discontinuation of Hormone Therapy in Hormone Receptor-Positive Breast Cancer Patients
por: Mao, Daqin, et al.
Publicado: (2019)

The Immunology of Hormone Receptor Positive Breast Cancer
por: Goldberg, Jonathan, et al.
Publicado: (2021)

Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor–Positive Metastatic Breast Cancer
por: Schwartzberg, Lee S., et al.
Publicado: (2010)

Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer
por: Gelmon, Karen A., et al.
Publicado: (2019)

Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor–Positive Metastatic Breast Cancer
por: Kim, Seul-Gi, et al.
Publicado: (2023)

Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer
por: Chen, Xue-Lian, et al.
Publicado: (2016)

Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer
por: Freelander, Allegra, et al.
Publicado: (2021)

Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance
por: Manso, Luis, et al.
Publicado: (2016)

Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
por: Shivapurkar, Narayan, et al.
Publicado: (2017)

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
por: Brett, Jamie O., et al.
Publicado: (2021)

Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer
por: Takada, Koji, et al.
Publicado: (2021)

Statin use in patients with hormone receptor‐positive metastatic breast cancer treated with everolimus and exemestane
por: Lee, Kyoungmin, et al.
Publicado: (2022)

A logarithmic model for hormone receptor-positive and breast cancer patients treated with neoadjuvant chemotherapy
por: Şeber, Erdoğan Selçuk, et al.
Publicado: (2023)

Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe
por: Moscetti, L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7dagjgk3ln0q8fmlvgdeqc7so1